Home Online Features Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Hand-out
Press Releases
Formosa Pharmaceuticals Inc.,  
November 28, 2024

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Nov. 28, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG ("Medvisis") in Switzerland and

logo salamanca press

Salamanca Press

email salamanca press
Local & Social